

Recap (CRISPR): How Bacteria Defend Against Phages

Defense Strategies

- **Prevent attachment** → change surface proteins.
Block DNA entry → membrane proteins stop injection.
Stop replication → block phage DNA copying.
Restriction-Modification (RM) → enzymes cut foreign DNA, protect own DNA.
Cell suicide → kill itself to stop phage spread.
CRISPR-Cas → adaptive immune system that remembers past phages.
-

CRISPR-Cas Immune System

What is CRISPR-Cas?

- A **genetic memory system** that helps bacteria recognize and destroy specific phages.
CRISPR = repeated DNA sequences with "spacer" DNA from old phage attacks.
Cas proteins = cutters that destroy matching phage DNA.

Steps in CRISPR Immunity

1. **Spacer Acquisition**
Cas1-Cas2 capture a piece of invading phage DNA and store it as a spacer.
2. **crRNA Biogenesis**
The CRISPR region is copied into RNA, then cut into guide RNAs (crRNAs).
3. **Interference**
Cas protein + crRNA find matching phage DNA and cut it.

PAM Sequence

- CRISPR targets phage DNA only if a **PAM** sequence is present.
This prevents CRISPR from cutting the bacterium's own DNA.

CRISPR Diversity

- Many types exist (Cas9 is only one example).
Some use one protein; others use many.
They cut DNA in different ways.
-

CRISPR in Genetic Disease Research

1. Studying Diseases

- **Monogenic diseases** (one gene): CRISPR can insert/remove mutations to study them.
Polygenic diseases (many genes): CRISPR can edit **multiple genes at once**, helping study complex diseases like diabetes or schizophrenia.

2. Disease Modeling

- **Cell models** – Edit cells in lab to see how mutations affect them.
Animal models – Edit animals (e.g., mice) to mimic human disease.
Xenografts – Transplant human tissue into animals for testing.
Chimeras – Animals containing human cells to study diseases more realistically.

3. Direct Gene Editing for Therapy

- Fix disease-causing mutations (e.g., sickle cell anemia).
Edit a patient's own cells → correct mutation → return cells to patient.
Potential future: edit embryos to prevent diseases (ethical concerns).

4. Challenges

- **Delivery** of CRISPR into the right cells.
Off-target effects – unintended DNA cuts.
Ethics – embryo editing, equity, long-term risks.

Off-Target Effects (Simple)

- CRISPR may accidentally cut similar DNA sequences → unwanted mutations.
Must be minimized for safe therapy.
-

Engineering Plants for Desired Traits

Vocabulary (Simplified)

- **Selective breeding** – choosing the best plants to reproduce.
 - **Mutation** – change in DNA.
 - **Mutagenesis** – creating random mutations.
 - **Transgenic** – plant has DNA from another organism.
 - **GMO** – genetically modified plant (may include foreign DNA).
-

Traditional Methods

Selective Breeding

- Humans pick plants with good traits (big fruits, disease resistance).
Works slowly over many generations.

Mutation Breeding

- Use radiation/chemicals to cause random mutations.
Faster but unpredictable.
-

Modern Genetic Methods - Transgenic Plants (GMOs)

- Add genes from other organisms (e.g., Bt toxin gene from bacteria).
Benefits: pest resistance, less pesticide use.

CRISPR Genome Editing

- Makes **precise** DNA changes without adding foreign DNA.
Faster and more targeted than older methods.
-

Advanced CRISPR Applications in Plants

- **Bioremediation** – plants that clean pollutants (e.g., heavy metals).
- **Better photosynthesis** → more carbon capture.
- **Biofuel production** – plants modified to produce more oils/sugars.

- **Bio-materials** – create plants that produce strong fibers or polymers.
- Personalized nutrition** – crops tailored for specific dietary needs.
- Climate resilience** – plants resistant to heat, drought, salinity.

Ethical & Environmental Concerns

- **Unintended effects** on ecosystems.
 - Loss of biodiversity** if only a few edited varieties dominate.
 - Gene flow** – edited genes spreading to wild plants.
 - Access/equity** – ensuring small farmers can benefit too.
-

Designing an effective guide RNA (gRNA) for CRISPR requires careful consideration of several factors to ensure high on-target activity and minimal off-target effects. The design process is typically aided by specialized online software tools.

Key Design Principles

- **Target Specificity:** The gRNA sequence should be unique in the genome to prevent off-target mutations. This is assessed by performing a genome-wide search for similar sequences and using off-target scoring algorithms.
- **Presence of a PAM Site:** The target sequence must be immediately adjacent to a Protospacer Adjacent Motif (PAM) sequence. For the commonly used *Streptococcus pyogenes* Cas9 (SpCas9), the PAM sequence is 5'-NGG-3', where N is any nucleotide. The gRNA does not include the PAM sequence itself.
- **On-Target Efficiency:** The guide should be highly likely to cut at the intended site. On-target efficiency is predicted by algorithms that consider the sequence composition and position of nucleotides.
- **GC Content:** An optimal GC content (typically 40-80%) contributes to gRNA stability and efficient binding to the target DNA.
- **Sequence Length:** The standard length for the target-specific portion of the gRNA is 20 nucleotides for SpCas9. Shorter, truncated gRNAs (17-18 nt)

can sometimes reduce off-target effects while maintaining efficiency in some systems.

- **Secondary Structure:** The gRNA should avoid forming complex secondary structures or self-dimerization, as this can interfere with Cas protein binding and function.
- **Chromatin Accessibility:** The target site should be in an accessible region of chromatin (euchromatin) for the Cas protein to bind effectively.

Experimental Goal Considerations

The specific goal of the experiment influences the design strategy:

- **Gene Knockout (NHEJ):** Target a common exon early in the gene's coding sequence to increase the chance of an out-of-frame mutation and a complete loss of protein function.
- **Gene Knock-in or Point Mutation (HDR):** The gRNA cleavage site must be very close (~30 nucleotides) to the desired edit location or the repair template homology arms for efficient homology-directed repair (HDR).
- **CRISPR Activation (CRISPRa) or Interference (CRISPRi):** Guide RNAs are designed to target specific regions upstream or nearby the transcription start site (TSS) to modulate gene expression.

Recommended Workflow

1. **Define the experimental goal** (knockout, knock-in, etc.).
2. **Identify potential gRNA sequences** near the target site that are adjacent to a PAM sequence using online design tools.
3. **Evaluate top candidates** using the on-target and off-target scores provided by the tools. Select guides with high on-target and low off-target scores.
4. **Consider using multiple gRNAs** for a single target to increase efficiency.
5. **Validate the selected gRNAs experimentally** in your specific cell system or organism to confirm efficiency and specificity.

For the most efficient design, it is highly recommended to use current bioinformatics tools such as **Benchling**, **CRISPOR**, **CHOPCHOP**, or the **Broad Institute GPP sgRNA Designer**, as they use sophisticated algorithms and large datasets to score potential gRNAs.

Gene editing techniques, such as CRISPR/Cas9, are used to create precise changes (like knockouts or specific point mutations) in the *ACE2* gene in cell lines and animal models. This allows scientists to:


- **Understand Normal Function:** By deactivating the gene (ACE2 knockout), researchers can study its essential roles in regulating blood pressure, heart function, kidney function, and placental development.
- **Model Diseases:** Editing the gene helps create models for studying conditions associated with ACE2 dysfunction, such as hypertension, heart failure, and diabetic nephropathy.
- **Investigate Genetic Variations:** Researchers can introduce specific single nucleotide polymorphisms (SNPs) found in the human population to understand how these natural variants affect disease susceptibility and severity, including outcomes in COVID-19 patients.

<https://chopchop.cbu.uib.no/>



Target	In	Using	For
<input type="text" value="ACE2"/>	<input type="text" value="Homo sapiens (hg38/GRCh38)"/>	<input type="text" value="CRISPR/Cas9"/>	<input type="text" value="knock-out"/>
<small>RefSeq/ENSEMBL/gene ID or genomic coordinates.</small>	<small>Add new species.</small>	<small>Change default PAM and guide length in Options.</small>	<small>Presets can be adjusted in Options.</small>

ACE2



https://www.idtdna.com/site/order/designtool/index/CRISPR_PREDESIGN

Search for predesigned gRNA Design custom gRNA [CRISPR-Cas9 gRNA checker](#)

Species

Homo sapiens

Input format

FASTA Sequence

Paste/Type input

Upload file

Enter up to 99 FASTA Sequences.

Please enter sequences in standard FASTA formatting.

GCCTCCATCGATATTAGCAAAGG

CHECK

CLEAR AND RESET

Do not enter the NGG/PAM site

☐ Checker analysis: **Sequence1**

Custom checker Alt-R CRISPR-Cas9 gRNA

Sequence	On-target score	Off-target score
GCCTCCATCGATATTAGCAA	67	79

[Show off-target details +](#) | [Show related products](#)

+ ADD TO DESIGN SET

CREATE NEW DESIGN

Note these comments before continuing

This gRNA is expected to be good.

Projects / CRISPR-CAS

Search

Type Filters

No items found

Folder

Entry

Protocol

DNA / RNA sequence

AA sequence

New DNA / RNA sequence

Import DNA / RNA sequences

Your workspace is empty!

Use the navigation bar on the left to create data.

CREATE NEW UPLOAD FILES IMPORT FROM DATABASE SELECT CHROMOSOMAL REGION

⚠ Imports from iGEM may not work due to limitations with their parts registry. Try uploading GenBank files instead.

Sequence

ACE2

Enter a species name for *ACE2* to search through Ensembl. If no exact matches are found, species will be ignored.

Genome

GRCh38

Search

X Clear

Create DNA / RNA sequence



This search is made possible thanks to work by Yates et al. and Zerbino et al.

Gene

ENSG00000130234

Species

GRCh38 (homo_sapiens)

Ensembl version

115

We'll import your data from the most recent Ensembl version.

Location

Chromosome X 15,494,566—15,607,236 (-)

☒ Import in sense orientation

Transcript

ACE2-201 (ENST00000252519)

Transcript

ACE2-201 (EN...

Import as

Genomic sequence

cDNA

You're about to import a genomic sequence with transcript-specific annotations.

Upstream bases

0

Downstream bases

0

Project folder*

CRISPR-CAS

Close

Import

Project

Entry

Protocol

DNA / RNA sequence

AA sequence

Oligo

Assembly

CRISPR

Entity from schema

Mixture

More

ACE2-201 (ENST00000252519)

SEQUENCE MAP

LINEAR MAP

DESCRIPTION

METADATA

RELEVANT ITEMS

Share

Create

Analyze

Copy

Create PDF

ACE2

31,14031,16031,18031,20031,220

TCCAAATCCCTTAGCTGAGAAATAAATATACATATCATTATGAATACTGTCAATTTTCTCATGTATCCTTATAGTAAGTACATCTTGAGGAATAATATTTGAGGTAGGAAAAGGTTTAGGGAATCGACTCTTTTATTATATATGTATAGTAATACTATGACAGTTAAAGAGTACATAGGAATATCATTCTAGTAACCTCTATTATAAACTCCAATCCTTT

ACE2

31,28031,30031,32031,340

ATTCTCTTTAACACAAACATCCACTGTCTATCTTCATCGTAATTTTATCCTTTTCTATTTTACTTTTCAGAACAGAAATAAACTCTCTGCTCAAAACAGCACTCAGGATGTTGGGTAAGAGAAATTGTGTTTGTAGGTGACAGTAGAAGTAGCATATAAATAGGAAAGATAAAATGAAAGTCTTTGTCTTTATTGAGGACGAGTTTGTCTGAGTGCTAACAAACC

434436438440442444446448

BTEINFLKQLALIVG

6326-45332: Region 10

BASES 112671

ASSEMBLY

SPLIT WORKSPACE

Design CRISPR guides: Guide parameters

Design CRISPR guides: Import sequence

Genome

GRCm38 (mm10, Mus musculus)

Don't see the genome you're looking for? We may be able to import it, [just ask](#).

Gene

Ace2 (ENSMUSG00000015405)

Location

chrX 164,139,332–164,188,420 (+)

Transcript

ACE2-002 (ENSMUST00000112271, CCDS3)

Ace2-002 (ENSMUST00000112271, CCDS3)

Import cDNA only

Upstream bp

0

Downstream bp

0

Sequence Name

Ace2 (ENSMUSG00000015405)

Design type

Single guide

Wild-type Cas9, single gRNA (higher efficiency)

Paired guides

Double Cas9 nickase, two gRNAs (lower off-target effects)

Guides for "base editing" (Komor et al., 2016)

C -> T (or G -> A) substitution, no dsDNA breaks

Guide length

20

Genome

GRCm38 (mm10, Mus musculus)

Don't see the genome you're looking for? We may be able to import it, [just ask](#).

PAM


NGG (SpCas9, 3' side)

Show advanced settings

Next

Save these as my default CRISPR settings

Finish



For a typical gene knockout experiment, the best exon to target is generally located within the **first third of the gene's protein-coding sequence (CDS)** and is an **exon that is common to all or most splice variants**.

Why this location is best:


- **Maximizes the chance of a functional knockout:**
 - Targeting the 5' end ensures that any frameshift mutations (insertions or deletions, or indels) caused by the non-homologous end joining (NHEJ) repair pathway will result in a truncated, non-functional protein.
 - An indel early in the gene is likely to introduce a premature stop codon, which can trigger nonsense-mediated decay (NMD) of the mRNA, further ensuring no functional protein is produced.
 - Avoiding the extreme N-terminus (first exon) helps mitigate the potential for the cell to use an alternative start codon downstream, which could result in a partially functional protein.
 - Avoiding the C-terminus ensures that a large portion of the protein is affected, rather than just the final, potentially non-essential, part.
- **Ensures all isoforms are targeted:** Choosing an exon present in all or most transcript variants (isoforms) means that the knockout will be effective across all forms of the protein, leading to a complete loss-of-function phenotype.
- **Minimizes compensatory mechanisms:** Targeting an "asymmetrical" exon (one whose length is not a multiple of 3 base pairs) ensures that even if the cell tries to skip the exon to restore the reading frame, the skipping itself will still cause a frameshift in the remaining sequence, maintaining the knockout effect.




Other key design considerations:

- **On-target activity and off-target effects:** Beyond location, the specific 20-nucleotide gRNA sequence must be optimized for high on-target efficiency and minimal off-target binding elsewhere in the genome.


Bioinformatics tools (like Benchling, CHOPCHOP, or Synthego's design tool) should be used for this analysis.

- **Chromatin accessibility:** The target region should be in an accessible region of the chromatin (euchromatin) for the Cas9 protein complex to bind efficiently.
- **GC content:** Aim for a GC content of 40-60% for stable gRNA-DNA binding.
- **Multiple gRNAs:** Designing and testing multiple gRNAs for a single gene (e.g., 2 or 3) is recommended to increase the success rate of achieving a complete knockout.





Check if this is hitting the intronic or exon region. **Routine Knockout:** Researchers typically use **2 to 4 high-quality gRNAs per gene** to ensure a high success rate and minimize the chance of false negatives.



- **Multiplexing:** For targeting multiple genes simultaneously or generating large genomic deletions, advanced cloning methods (like Golden Gate Assembly) allow for the delivery of up to **10, or even up to 30, different gRNAs** in a single vector, although efficiency may decrease with higher numbers.
- **Genome-wide Screens:** Pooled CRISPR screens use libraries containing tens of thousands of unique gRNAs to target every gene in the genome, with typically 3-6 different gRNAs per gene represented in the library pool.
- **Target Region Constraints:** For specific applications like CRISPR activ

On-Target Sites

- **Definition:** The specific, user-defined DNA sequence (typically 20 nucleotides long for Cas9) immediately upstream of a Protospacer Adjacent Motif (PAM, e.g., NGG for *S. pyogenes* Cas9) that the gRNA is designed to target.

- **Goal:** Maximize the binding and cleavage efficiency at this specific site to ensure the desired genetic modification (e.g., knockout or knock-in) occurs effectively.
- **Design Considerations:**
 - **Location:** For a gene knockout, targeting an early exon is often preferred to ensure a functional protein is not produced. For other applications (knock-in, activation/repression), the location might be more constrained, requiring a balance between location and sequence efficiency.
 - **Efficiency Score:** Bioinformatics tools provide an on-target activity score (usually 0-1), with higher scores indicating a greater likelihood of a successful edit.
 - **Chromatin Accessibility:** The target region should be in an accessible chromatin state for the Cas9 complex to bind efficiently.

Off-Target Sites

- **Definition:** Other locations in the genome that have enough sequence similarity (partial homology) to the gRNA target sequence (including the PAM) that the Cas9 complex can still bind and cleave, even with a few mismatches.
- **Concern:** Off-target activity can lead to unintended, non-specific genetic modifications, which can confound experimental results, cause unwanted phenotypes, or, in a therapeutic context, pose serious safety risks (e.g., disrupting a tumor-suppressor gene).
- **Design Considerations to Minimize Risk:**
 - **Specificity Score:** Design tools provide an off-target score, with higher scores typically indicating a lower potential for off-target activity (fewer potential off-target sites or fewer close matches).
 - **Sequence Uniqueness:** The chosen 20nt target sequence should be as unique as possible within the entire genome.

- **Mismatch Location:** Mismatches are better tolerated at the 5' end of the gRNA sequence (distal to the PAM) than at the 3' end (proximal to the PAM or "seed" region), so a good gRNA will avoid off-target sequences with perfect matches in the seed region.
- **gRNA Length/Modifications:** Using a slightly shorter gRNA (e.g., 17-18 nt) or incorporating specific chemical modifications can increase specificity.
- **Use of High-Fidelity Cas9:** Utilizing engineered high-fidelity Cas9 variants (like SpCas9-HF1 or HypaCas9) that are less tolerant of mismatches can significantly reduce off-target effects.
- **Validation:** Potential off-target sites predicted by in silico tools should be verified experimentally (e.g., via targeted deep sequencing or whole-genome sequencing) to confirm their activity or absence.

<https://www.ncbi.nlm.nih.gov/nuccore/EU899414.1>

Escherichia coli strain TW14359 flagellar biosynthesis protein FlhB (ECs2590) gene, complete cds

GenBank: EU899414.1



[FASTA](#) [Graphics](#)

[Go to:](#) ☒

LOCUS	EU899414	1149 bp	DNA	linear	BCT 08-JUN-2009
DEFINITION	Escherichia coli strain TW14359 flagellar biosynthesis protein FlhB (ECs2590) gene, complete cds.				
ACCESSION	EU899414				
VERSION	EU899414.1				
KEYWORDS	.				
SOURCE	Escherichia coli				
ORGANISM	Escherichia coli Bacteria; Pseudomonadati; Pseudomonadota; Gammaproteobacteria; Enterobacterales; Enterobacteriaceae; Escherichia.				
REFERENCE	1 (bases 1 to 1149)				
AUTHORS	Leopold,S.R., Magrini,V., Holt,N.J., Shaikh,N., Mardis,E.R., Cagno,J., Ogura,Y., Iguchi,A., Hayashi,T., Mellmann,A., Karch,H., Besser,T.E., Sawyer,S.A., Whittam,T.S. and Tarr,P.I.				
TITLE	A precise reconstruction of the emergence and constrained radiations of Escherichia coli O157 portrayed by backbone concatenomic analysis				
JOURNAL	Proc. Natl. Acad. Sci. U.S.A. 106 (21), 8713-8718 (2009)				
PUBMED	19439656				
REFERENCE	2 (bases 1 to 1149)				
AUTHORS	Leopold,S.R., Magrini,V., Holt,N.J., Shaikh,N., Mardis,E.R., Cagno,J., Ogura,Y., Iguchi,A., Hayashi,T., Mellmann,A., Karch,H., Besser,T.E., Sawyer,S.A., Whittam,T.S. and Tarr,P.I.				

https://www.snapgene.com/plasmids/crispr_plasmids/pET28a_Cas9-Cys

The screenshot displays the Benchling interface for a sequence map. The top navigation bar includes tabs for 'SEQUENCE MAP', 'LINEAR MAP', 'DESCRIPTION', 'METADATA', and 'RELEVANT ITEMS'. The 'SEQUENCE MAP' tab is active, showing a sequence map with various restriction enzyme sites (SphI, BspI, BseYI, BclI, HpyCH4III, HinfI, FliI, BsoBI, AwaI, BclI, BglI) and a 'New annotation' form on the right. The form includes fields for 'Name' (start), 'Position' (200 - 202), 'Annotation type' (Annotation type), 'Color' (yellow), 'Strand' (Forward), and 'Notes' (Notes). The sequence map shows a sequence with a highlighted region (200-202) and a 'New annotation' form on the right. The form includes fields for 'Name' (start), 'Position' (200 - 202), 'Annotation type' (Annotation type), 'Color' (yellow), 'Strand' (Forward), and 'Notes' (Notes). The sequence map also shows a 'source' annotation for 'ECs2590 gene' and 'ECs2590 CDS (flagellar biosynthesis protein FlhB)'.



pET28a/Cas9-Cys EU899414

SEQUENCE MAP DESIGN PRIMER LINEAR MAP DESCRIPTION METADATA RELEVANT ITEMS

Primer Pair Single Primer Primer Pair

Jump to Primer Set from Selection

Design

Strand Forward Reverse

Bases 5' 3' 5' 3'

Primer must be at least 6 bp.

3' Location 1 200

Overhang 0 bp 0 bp

Cut Site Enzyme

Use the dropdown above to look up restriction sites.

Verify

Check Secondary Structure at 37 °C

BASES 1149 START 200 END 219 LENGTH 20 GC 30.00% MELTING TEMP 44.3 °C ASSEMBLY SPLIT WORKSPACE

pET28a/Cas9-Cys EU899414

SEQUENCE MAP

Create Analyze Copy Create PDF

Linear Map Description Metadata Design Primer DESIGN PRIMER

Primer Pair Jump to Primer Set from Selection

Design

Strand Forward Reverse

Bases 5' 3' 5' 3'

Primer must be at least 6 bp.

3' Location 206 1

Overhang 11 0

Cut Site NheI GCTAGC

Use the dropdown above to look up restriction sites.

Verify

Check Secondary Structure at 37 °C

BASES 1149 START 174 END 206 LENGTH 33 GC 54.55% MELTING TEMP 67.6 °C ASSEMBLY SPLIT WORKSPACE

pET28a/Cas9-Cys EU899414

SEQUENCE MAP

Create Analyze Copy Create PDF

Linear Map Description DESIGN PRIMER METADATA RELEVANT ITEMS

Primer Pair Jump to Primer Set from Selection

Design

Strand Forward Reverse

Bases 5' 3' 5' 3'

Primer must be at least 6 bp.

3' Location 204 1

Overhang 10 10

Cut Site EcoRI GAATTC

Use the dropdown above to look up restriction sites.

The specified primer pair does not result in a valid product. Make sure that the forward primer binds before the reverse primer if the sequence is linear.

Verify

Check Secondary Structure at 37 °C

BASES 1149 START 1121 END 1149 LENGTH 29 GC 37.93% MELTING TEMP 58.0 °C ASSEMBLY SPLIT WORKSPACE

The image displays two screenshots of the Benchling software interface, specifically the 'DESIGN PRIMER' and 'Design' tabs, illustrating the process of designing primers for the ECs2590 gene (flagellar biosynthesis protein FlhB).

Top Screenshot (DESIGN PRIMER Tab):

- Sequence Map:** Shows the ECs2590 gene sequence (1,030 to 1,100 bp) and the ECs2590 CDS (1,110 to 1,140 bp). The primer pair is highlighted in green.
- Primer Pair:**
 - Primer-F:** 5'-tggcctgggtctggaactgaacgctggcgtctggctgggacagcgccctgtacaacctactcatcttcgggtgccaccgaccagaccgttgactttgcgaccgcagaccgaccacctgtgcgggacatgttggatgagtagaaggccacgg-3'
 - Primer-R:** 5'-ggaagccctggattttattaaagagaacccacccatgagtaa-3'
- GC Content:** 57.14% (Primer-F), 44.00% (Primer-R)
- Length:** 38 bp (Primer-F), 35 bp (Primer-R)
- Product Size:** 20 bp
- T_m Diff:** -8.00°C
- Save:** The primer pair is saved to the 'Primers' folder.

Bottom Screenshot (Design Tab):

- Strand:** Forward and Reverse strands are shown.
- Bases:** The primer sequences are displayed with the leader sequence (atta/attc) highlighted in yellow.
- 3' Location:** The primer-F is located at position 176, and the primer-R is located at position 1121.
- Overhang:** The overhang length is set to 10 bp.
- Cut Site:** The restriction site is NheI, which recognizes the sequence GCTAGC.
- Verify:** The secondary structure is checked, showing a melting temperature (T_m) of 64.4°C for the forward primer and 58.0°C for the reverse primer.

A leader sequence (atta/attc) in primer design is a small number of additional base pairs added to the 5' end of a primer to facilitate its function, most commonly to help a restriction enzyme cut more efficiently when cloning. This sequence of 3-6 nucleotides typically includes a restriction enzyme site and is positioned before the region of the primer that will bind to the DNA template.

EU899414

LINEAR MAP DESCRIPTION METADATA RELEVANT ITEMS

Analyze Copy Create PDF

Imported from database: NCBI
Entry: EU899414
Description: Escherichia coli str.
FliH (ECs2590) gene, complete

Primer Pair Information

Link Primers

	Name	T _m
Forward Primer	primer-F	64.4°C
Reverse Primer	Primer-R	58.0°C

Product Size 1020 bp
T_m Difference -6.4° C

Create PCR Product Secondary Structure

pET28a/Cas9-Cys

SEQUENCE MAP

AAATAATTTTGTTTAACTTAAGAAGGAGATATACCATGGGAGCAGCCATCATCATCATCACAGCAGCGGCTGG
TTTATTAAACAATTGAAATCTCTCTATATGGTACCGCTGTCGGTAGTAGTAGTAGTGTCTGCGCGGACCC

RBS 6xHis

2,770 2,780 2,790 2,800 2,810 2,820 2,830 2,840

NcoI

SalI HincII SacI Eco53kI BamHI

NdeI BmtI

TGCGCGCGGAGCCATATGGCTAGCATGACTGGTGACAGCAAAATGGGTGCGGATCCGAATTCGAGCTCCGTCGACA
ACGGCGCGCGCTGGTATACCGATCGTACTGACCACTGTGTTTACCCAGCGCTAGGCTTAAGCTCGAGGACAGCTGT

thro...ite T7 tag (gene 10 leader)

BASES 9546 INSERT 2905

LINEAR MAP PLASMID DESCRIPTION METADATA RELEVANT ITEMS

pET28a/Cas9-Cys (9546 bp)

PaqCI KpnI XbaI BspDI NruI SmaI PspMI XmaI SspI AsiSI PvuI ClaI PciI

EcoRI

1,000 2,000 3,000 4,000 5,000 6,000 7,000 8,000 9,000

ASSEMBLY SPLIT WORKSPACE

pET28a/Cas9-Cys

SEQUENCE MAP

LINEAR MAP PLASMID DESCRIPTION METADATA RELEVANT ITEMS

17 promoter lac operator

RBS 6xHis

2,680 2,700 2,720 2,740 2,760 2,780 2,800 2,820 2,840

NdeI BmtI BamHI EcoRI HincII SalI SacI NotI HindIII BaeI KpnI Acc65I

GGGGACACCCAGCCACAGCATCAAGAGAACTGTGGCGGCTGCTGTTCAGACGGGAGACCGGAGGCGACCGGCTGAAGCGACCGCGCGCGGCTACACCGCGCAAGAACCGCATCTGCTACTCGAGGAGATCTTCAGCAAGAGATGGCAAGGTGGACGACAGCTTCTTC
CCGCTGTGGTGGCGGCTGTCTAGTTTCTTCTTGGAGTACGGCGGAGACAGCATGTGCGGCTGTGGCGGCTGCGGTGGCGGCTGCTGGTGGCGGCGGCGGATGTGGCGGCTGCTTGGCGTACAGCATGGACGCTCTCTAGAAAGTCTGCTACCGGTTCCACCTGCTGTGGAAGAG

T7 tag (gene 10 leader) Cas9

2,860 2,880 2,900 2,920 2,940 2,960 2,980 3,000 3,020 3,040

SbfI

BASES 9546 START 2865 END 2905 LENGTH 41 GC 58.54% MELTING TEMP 73.0 °C

ASSEMBLY SPLIT WORKSPACE

Sequence map of pET28a/Cas9-Cys (9.5 kb) and EU899414 [150-1149]. The map shows the T7 promoter, lac operator, RBS, and 6xHis tag. Restriction sites for NdeI, BmtI, BamHI, EcoRI, HincII, SalI, SmaI, NotI, HindIII, BaeI, KpnI, and Acc65I are indicated. The sequence is shown with the T7 promoter and lac operator. The 6xHis tag is highlighted. The sequence is shown with the T7 promoter and lac operator. The 6xHis tag is highlighted.

PREVIEW

0 ERRORS AND 0 WARNINGS
✓ Looks like everything checks out

Reverse Orientation
Jump to Selection
View Enzyme Activity

pET28a/Cas9-Cys
9.5 kb · EcoRI, NheI

Insert

BASES 9546 START 2905 END 2865 LENGTH 9507 GC 56.71% MELTING TEMP 831.1°C

ASSEMBLY SPLIT WORKSPACE

Sequence map of pET28a/Cas9-Cys (9.5 kb) and EU899414 [150-1149]. The map shows the T7 promoter, lac operator, RBS, and 6xHis tag. Restriction sites for NdeI, BmtI, BamHI, EcoRI, HincII, SalI, SmaI, NotI, HindIII, BaeI, KpnI, and Acc65I are indicated. The sequence is shown with the T7 promoter and lac operator. The 6xHis tag is highlighted.

PREVIEW

0 ERRORS AND 0 WARNINGS
✓ Looks like everything checks out

Reverse Orientation
Jump to Selection
View Enzyme Activity

pET28a/Cas9-Cys
9.5 kb · EcoRI, NheI

EU899414 [150-1149]
1.0 kb · NheI, EcoRI

Insert

BASES 1020 START 6 END 1011 LENGTH 1006 GC 54.37% MELTING TEMP 816.1°C

ASSEMBLY SPLIT WORKSPACE

Sequence map of pET28a/Cas9-Cys (9.5 kb) and EU899414 [150-1149]. The map shows the T7 promoter, lac operator, RBS, and 6xHis tag. Restriction sites for NdeI, BmtI, BamHI, EcoRI, HincII, SalI, SmaI, NotI, HindIII, BaeI, KpnI, and Acc65I are indicated. The sequence is shown with the T7 promoter and lac operator. The 6xHis tag is highlighted.

PREVIEW

0 ERRORS AND 0 WARNINGS
✓ Looks like everything checks out

Reverse Orientation
Jump to Selection
View Enzyme Activity

pET28a/Cas9-Cys
9.5 kb · EcoRI, NheI

EU899414 [150-1149]
1.0 kb · NheI, EcoRI

Insert

BASES 10513 INSERT 2853

ASSEMBLY SPLIT WORKSPACE

